File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009

TitleManagement of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009
Authors
Issue Date2009
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/j.lancetoncol
Citation
The Lancet Oncology, 2009, v. 10 n. 11, p. 1093-1101 How to Cite?
AbstractT-cell and natural-killer (NK)-cell lymphomas are neoplasms with geographical variations in frequencies. T-cell lymphomas are more prevalent in Asia than in Europe and North America, and NK-cell lymphomas occur almost exclusively in Asia and South America. These low frequencies mean that the diagnosis and optimum treatment of patients with T-cell and NK-cell lymphomas have not been studied prospectively in randomised controlled trials. Because T-cell and NK-cell lymphomas are more prevalent in Asia, the establishment of management recommendations by Asian oncologists in collaboration with international experts is pertinent. This review outlines guidelines commensurate with different levels of health-care resources and expertise. Consensus statements were formulated for diagnosis, staging, follow-up, and treatment approaches in patients with T-cell and NK-cell lymphomas-aimed at unifying the design of studies and interpretation of results. For patients not in clinical trials, consensus opinions offer useful guidelines on optimum management. © 2009 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/125062
ISSN
2021 Impact Factor: 54.433
2020 SCImago Journal Rankings: 13.530
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorAnderson, BOen_HK
dc.contributor.authorAdvani, Ren_HK
dc.contributor.authorKim, WSen_HK
dc.contributor.authorLevine, AMen_HK
dc.contributor.authorLim, STen_HK
dc.date.accessioned2010-10-31T11:09:17Z-
dc.date.available2010-10-31T11:09:17Z-
dc.date.issued2009en_HK
dc.identifier.citationThe Lancet Oncology, 2009, v. 10 n. 11, p. 1093-1101en_HK
dc.identifier.issn1470-2045en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125062-
dc.description.abstractT-cell and natural-killer (NK)-cell lymphomas are neoplasms with geographical variations in frequencies. T-cell lymphomas are more prevalent in Asia than in Europe and North America, and NK-cell lymphomas occur almost exclusively in Asia and South America. These low frequencies mean that the diagnosis and optimum treatment of patients with T-cell and NK-cell lymphomas have not been studied prospectively in randomised controlled trials. Because T-cell and NK-cell lymphomas are more prevalent in Asia, the establishment of management recommendations by Asian oncologists in collaboration with international experts is pertinent. This review outlines guidelines commensurate with different levels of health-care resources and expertise. Consensus statements were formulated for diagnosis, staging, follow-up, and treatment approaches in patients with T-cell and NK-cell lymphomas-aimed at unifying the design of studies and interpretation of results. For patients not in clinical trials, consensus opinions offer useful guidelines on optimum management. © 2009 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/j.lancetoncolen_HK
dc.relation.ispartofThe Lancet Oncologyen_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - standards - therapeutic useen_HK
dc.subject.meshAsia - epidemiologyen_HK
dc.subject.meshCongresses as Topicen_HK
dc.subject.meshDeveloping Countries - economicsen_HK
dc.subject.meshEvidence-Based Medicineen_HK
dc.subject.meshHealth Services Accessibilityen_HK
dc.subject.meshHealthcare Disparitiesen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunotherapyen_HK
dc.subject.meshKiller Cells, Natural - pathologyen_HK
dc.subject.meshLymphoma - diagnosis - mortality - pathology - therapyen_HK
dc.subject.meshLymphoma, T-Cell - diagnosis - mortality - pathology - therapyen_HK
dc.subject.meshMedical Oncology - economics - standardsen_HK
dc.subject.meshNeoplasm Stagingen_HK
dc.subject.meshPredictive Value of Testsen_HK
dc.subject.meshRadiotherapy, Adjuvanten_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleManagement of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1470-2045&volume=10&issue=11&spage=1093&epage=1101&date=2009&atitle=Management+of+T-cell+and+natural-killer-cell+neoplasms+in+Asia:+consensus+statement+from+the+Asian+Oncology+Summit+2009en_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S1470-2045(09)70265-7en_HK
dc.identifier.pmid19880063-
dc.identifier.scopuseid_2-s2.0-71249097862en_HK
dc.identifier.hkuros180772en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-71249097862&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue11en_HK
dc.identifier.spage1093en_HK
dc.identifier.epage1101en_HK
dc.identifier.isiWOS:000271852800019-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridAnderson, BO=22937050900en_HK
dc.identifier.scopusauthoridAdvani, R=7003342788en_HK
dc.identifier.scopusauthoridKim, WS=34975082200en_HK
dc.identifier.scopusauthoridLevine, AM=26643352000en_HK
dc.identifier.scopusauthoridLim, ST=8653861000en_HK
dc.identifier.citeulike6064824-
dc.identifier.issnl1470-2045-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats